Treeline Biosciences surfaced from stealth with disclosures of $200 million raised in a series A extension and announced three oncology drug candidates in clinical testing. The Massachusetts-based startup has raised approximately $1.1 billion to date from prominent biotech investors. Their pipeline includes a protein degrader targeting BCL6 in lymphoma, a broad KRAS inhibitor effective across multiple mutations, and an EZH2 inhibitor licensed from Jiangsu Hengrui Pharmaceuticals for T cell lymphomas. Treeline departs from traditional milestone-driven funding models, aiming to support multiple complementary programs concurrently, signaling an agile and expansive approach to cancer therapy development.